Currently, accumulated evidence shows that splicing aberrations could also contribute to this process.[44, 45] To explore how RBP dysregulation is involved in drug resistance, specifically in glioblastoma (GBM), we collected RNA‐seq of 45 patient‐derived cells with treatment response to Foretinib, a multi‐kinase inhibitor of MET and VEGFRs[46] (Figure 4P). Here, MET is linked to glioblastoma.